Group items tagged

Pétrole, automobile, banque et assurance ne sont que quelques-unes des industries forcées à la mutation, après les télécoms ou la poste. L'industrie pharmaceutique, construite sur une R&D alimentant la visite médicale en nouvelles molécules, illustre cette réinvention nécessaire de leur core business. Si certains regrettaient le conformisme du modèle, durant des décennies, la pharmacie a soigné de plus en plus de maladies, a connu une croissance soutenue et a dégagé des marges finançant l'innovation. Elle fait désormais face à trois ruptures majeures.

Digestible microchips embedded in drugs may soon tell doctors whether a patient is taking their medications as prescribed.  These sensors are the first ingestible devices approved by the US Food and Drug Administration (FDA). To some, they signify the beginning of an era in digital medicine.

"En Californie, la mSanté n'est pas l'apanage des médecins et des hôpitaux. Une pharmacie locale, Bi-Rite, a lancé un programme de messages automatiques pour rappeler aux patients qu'ils doivent prendre leurs médicaments."

The health industry has not always been a leader in technology adoption. The current "high touch" model where caretakers deliver services within silos of care cannot be sustained because of high costs and other concerns. Making this even more of a challenge is a payment system that leaves little room for improved performance due to financial incentives. That's changing and the industry is moving toward greater "connectedness."  This new model will feature these characteristics: data-based transparency, personalized care, and consumer-directed care. Strategies such as predictive medicine and personalized care could allow players to create value in this new environment. This report outlines how executives should react and take advantage.